SCHEMBL1290937

SCHEMBL1290937

CNc1ccc(Oc2ccc(NC(=O)c3ccc(C(F)(F)F)cc3F)cn2)c(C)c1

nearest known ligand 0.60

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.51
SCN8A Q9UQD0 2/20 0.49
SCN10A Q9Y5Y9 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1291145 0.99 RAB9A (0.50) RAB9ASCN8ASCN10A
SCHEMBL1290825 0.92 GAA (0.50) RAB9ASCN8ASCN10A
Hydrochloric Acid SCHEMBL1290688 0.91 RAB9A (0.49) RAB9ASCN8ASCN10A
SCHEMBL1290678 0.90 SCN8A (0.49) RAB9ASCN8ASCN10A
Hydrochloric Acid SCHEMBL1290839 0.89 SCN8A (0.49) RAB9ASCN8ASCN10A
SCHEMBL1290899 0.87 RAB9A (0.60) RAB9A
SCHEMBL31305897 0.87 RAB9A (0.60) RAB9A
Hydrochloric Acid SCHEMBL31305933 0.86 RAB9A (0.59) RAB9A
SCHEMBL1290620 0.86 GAA (0.57) RAB9A
Hydrochloric Acid SCHEMBL1290649 0.86 RAB9A (0.59) RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250134872-A1 ANTITUMOR COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-05-01 US claimed
CN-119792535-A Antitumor composition 大塚制药株式会社 2025-04-11 CN claimed
US-12220410-B2 Antitumor composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-02-11 US claimed
US-20240417376-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-12-19 US claimed
US-20230139808-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-05-04 US claimed
US-20220202794-A1 ANTITUMOR COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-06-30 US claimed
EP-3946328-A1 ANTITUMOR COMPOSITION Otsuka Pharmaceutical Co., Ltd. (JP) 2022-02-09 EP claimed
CN-113597309-A Antitumor composition 大塚制药株式会社 2021-11-02 CN claimed
US-20210017134-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-01-21 US claimed
WO-2020196665-A1 ANTITUMOR COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-10-01 WO claimed
US-20200031773-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-01-30 US claimed
US-20180265471-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2018-09-20 US claimed
US-20170298023-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMA CO LTD (JP) 2017-10-19 US claimed
US-20150105432-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMACEUTICAL CO., LTD. 2015-04-16 US claimed
US-8946437-B2 4-(methylaminophenoxy)pyrdin-3-yl-benzamide derivatives for treating cancer OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-02-03 US claimed
EP-2624833-B1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMA CO LTD (JP) 2014-12-10 EP claimed
US-20130267565-A1 4- (METHYLAMINOPHENOXY) PYRDIN -3- YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-10-10 US claimed
US-20250134872-A1 ANTITUMOR COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-05-01 US disclosed
EP-2624833-A1 4- (METHYLAMINOPHENOXY) PYRDIN- 3 - YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER Otsuka Pharmaceutical Co., Ltd. (JP) 2013-08-14 EP disclosed
WO-2012046825-A1 4- (METHYLAMINOPHENOXY) PYRDIN- 3 - YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105432-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER HCCS, IDH2, GLS2 RAB9A 1655/4885SCN8A 4345/4885SCN10A 4295/4885
US-20250134872-A1 ANTITUMOR COMPOSITION MCL1, BAK1, BCL2 RAB9A 2856/4885SCN8A 4552/4885SCN10A 3712/4885
US-20230139808-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER HCCS, IDH2, MDH2 RAB9A 1752/4885SCN8A 4489/4885SCN10A 4407/4885
US-20130267565-A1 4- (METHYLAMINOPHENOXY) PYRDIN -3- YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER HCCS, MDH2, IDH2 RAB9A 1673/4885SCN8A 4397/4885SCN10A 4344/4885
US-20180265471-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER HCCS, GLS2, IDH2 RAB9A 1652/4885SCN8A 4332/4885SCN10A 4287/4885
US-20240417376-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER HCCS, GLS2, IDH2 RAB9A 1652/4885SCN8A 4332/4885SCN10A 4287/4885
US-20170298023-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER IDH2, MDH2, HCCS RAB9A 1651/4885SCN8A 4452/4885SCN10A 4400/4885
US-20200031773-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER HCCS, GLS2, IDH2 RAB9A 1652/4885SCN8A 4332/4885SCN10A 4287/4885
US-20220202794-A1 ANTITUMOR COMPOSITION MCL1, BAK1, BCL2 RAB9A 2856/4885SCN8A 4552/4885SCN10A 3712/4885
US-20210017134-A1 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER HCCS, GLS2, IDH2 RAB9A 1652/4885SCN8A 4332/4885SCN10A 4287/4885
US-12220410-B2 Antitumor composition MCL1, BAK1, BCL2 RAB9A 2856/4885SCN8A 4552/4885SCN10A 3712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.